Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation.

AuthorsAnaig Dagorne, Nathalie Douet-Guilbert, Isabelle Quintin-Roue, Gaelle Guillerm, Marie-Anne Couturier, Christian Berthou, Jean-Christophe Ianotto
JournalAnnals of hematology (Ann Hematol) Vol. 92 Issue 3 Pg. 407-9 (Mar 2013) ISSN: 1432-0584 [Electronic] Germany
PMID22941306 (Publication Type: Case Reports, Letter)
Chemical References
  • Drug Carriers
  • Interferon-alpha
  • Recombinant Proteins
  • peginterferon alfa-2a
  • Polyethylene Glycols
  • Drug Carriers (metabolism)
  • Fatal Outcome
  • Humans
  • Interferon-alpha (metabolism, therapeutic use)
  • Leukemia, Myeloid, Acute (complications, diagnosis, therapy)
  • Male
  • Middle Aged
  • Polyethylene Glycols (metabolism, therapeutic use)
  • Primary Myelofibrosis (complications, diagnosis, therapy)
  • Recombinant Proteins (metabolism, therapeutic use)
  • Remission Induction
  • Stem Cell Transplantation
  • Thrombocytosis (complications, diagnosis, therapy)
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: